Consistently, PD-L1 reconstitution partially reversed ATXN3 deletion–induced tumor suppression, indicating that additional unknown targets possibly exist for ATXN3 to achieve tumor immune evasive functions. The gene discussed is ATXN3; the disease is neoplasm.